A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

About the study

This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD). Participants will be randomized to receive inclacumab or placebo.

Study point of contact

Carolyn Hoppe, MD
[email protected]


15 United States sites

6 Brazil sites

5 Kenya sites

5 Nigeria sites

4 Turkey sites

3 France sites

3 Italy sites

2 Lebanon sites

2 United Kingdom sites

1 Oman site

1 Germany site

1 Tanzania site

1 Saudi Arabia site


> 12 Years


HbSS, HbSC, HbSB0 thalassemia


Phase 3

Study type






participation requirements

Participant has a confirmed diagnosis of SCD (HbSS, HbSC, HbSB0 thalassemia, or HbSB+ thalassemia genotype).

Documentation of SCD genotype is required and may be based on documented history of laboratory testing or confirmed by laboratory testing during Screening.

Participant is male or female, ≥ 12 years of age at the time of informed consent.

Participant has experienced between 2 and 10 VOCs within the 12 months prior to the Screening Visit as determined by documented medical history. A prior VOC is defined as an acute episode of pain which:

Has no medically determined cause other than a vaso-occlusive event, and
Results in a visit to a medical facility (hospital, emergency department, urgent care center, outpatient clinic, or infusion center) or results in a remote contact with a healthcare provider; and
Requires parenteral narcotic agents, parenteral nonsteroidal anti- inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics.
Participants receiving erythropoiesis-stimulating agents (ESA, e.g., erythropoietin [EPO]) must be on a stable dose for at least 90 days prior to the Screening Visit and expected to continue with the stabilized regimen throughout the course of the study.
Participants receiving hydroxyurea (HU), L-glutamine, or voxelotor (Oxbryta®) must be on a stable dose for at least 30 days prior to the Screening Visit and expected to continue with the stabilized regimen throughout the course of the study.

participation restrictions

Participant is receiving regularly scheduled red blood cell (RBC) transfusion therapy (also termed chronic, prophylactic, or preventative transfusion).
Participant is taking or has received crizanlizumab (ADAKVEO®) within 90 days prior to the Screening Visit
Participant weighs > 133 kg (292 lbs.).

Other protocol-defined Inclusion/Exclusion may apply.


  • Mobile, Alabama, United States, University of South Alabama Children's and Women's Hospital
  • Phoenix, Arizona, United States, Phoenix Children's Hospital
  • Little Rock, Arkansas, United States, Arkansas Children's Hospital
  • Irvine, California, United States, UC Irvine Medical Center
  • Oakland, California, United States, UCSF Benioff Children's Hospital
  • Tampa, Florida, United States, University of South Florida
  • Atlanta, Georgia, United States, Children's Healthcare of Atlanta at Scottish Rite Hospital
  • Chicago, Illinois, United States, University of Illinois at Chicago
  • Chicago, Illinois, United States, Rush University Medical Center
  • Boston, Massachusetts, United States, Brigham and Women's Hospital
  • Ann Arbor, Michigan, United States, University of Michigan
  • Bronx, New York, United States, Jacobi Medical Center
  • Buffalo, New York, United States, Erie County Medical Center
  • Durham, North Carolina, United States, Duke University Medical Center
  • Memphis, Tennessee, United States, St Jude Children's Research Hospital
  • Porto Alegre, Rio Grande Do Sul, Brazil, Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
  • Ribeirão Preto, São Paulo, Brazil, Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP
  • São José Do Rio Preto, São Paulo, Brazil, Fundação Faculdade Regional de Medicina de São José Do Rio Preto
  • Rio De Janeiro, Brazil, HEMORIO - Unidade de Pesquisa Clínica
  • São Paulo, Brazil, Hospital Samaritano
  • São Paulo, Brazil, Hospital Santa Marcelina
  • Toulouse, Haute-Garonne, France, CHU de Toulouse - IUCT ONCOPOLE
  • Bobigny, Seine-Saint-Denis, France, Hopital Avicenne
  • Créteil, Val-de-Marne, France, Hopital Henri Mondor
  • Regensburg, Bayern, Germany, Universitätsklinikum Regensburg
  • Genova, Liguria, Italy, E O Ospedali Galliera
  • Padova, Veneto, Italy, Azienda Ospedale Università Padova
  • Napoli, Italy, Azienda Ospedaliera Universitaria (AOU) dell'Università degli Studi della Campania Luigi Vanvitelli
  • Siaya, Nyanza, Kenya, KEMRI/CRDR Siaya Clinical Research Annex
  • Kisumu, Western, Kenya, Strathmore University
  • Eldoret, Kenya, International Cancer Institute (ICI)
  • Nairobi, Kenya, KEMRI CRDR Clinical Research Clinic Nairobi
  • Nairobi, Kenya, Gertrude's Children's Hospital
  • Beirut, Lebanon, American University of Beirut Medical Center
  • Tripoli, Lebanon, Nini Hospital
  • Calabar, Cross River, Nigeria, University of Calabar Teaching Hospital
  • Idi Araba, Lagos, Nigeria, Lagos University Teaching Hospital Haematology
  • Abuja, Nigeria, University of Abuja Teaching Hospital
  • Enugu, Nigeria, University of Nigeria
  • Kano, Nigeria, Aminu Kano Teaching Hospital
  • Muscat, Al-Khodh, Oman, Sultan Qaboos University Hospital
  • Jazan, Saudi Arabia, Prince Mohamed Bin Nasser Hospital
  • Mbeya, Tanzania, NIMR-Mbeya Medical Research Center
  • Adana, Turkey, Baskent University Medical Faculty Adana Dr. Turgut Noyan Practice and Research Center
  • Adana, Turkey, Acibadem Adana Hospital
  • Ankara, Turkey, Hacettepe University Ihsan Dogramaci Children's Hospital
  • Mersin, Turkey, Mersin University Medical Faculty
  • London, United Kingdom, Guys Hospital
  • London, United Kingdom, Kings College Hospital
Last updated 2022-08-15